Literature DB >> 32004206

Toll-like receptor 7-driven lupus autoimmunity induces hypertension and vascular alterations in mice.

Iñaki Robles-Vera1, Néstor De La Visitación1, Marta Toral2,3, Manuel Sánchez1,4, Manuel Gómez-Guzmán1,4, Francisco O'valle4,5, Rosario Jiménez1,3,4, Juan Duarte1,3,4,6, Miguel Romero1,4.   

Abstract

OBJECTIVE: To investigate whether toll-like receptor 7 (TLR7) activation induces an increase in blood pressure and vascular damage in wild-type mice treated with the TLR7 agonist imiquimod (IMQ).
METHODS: Female BALB/c mice (7-9 week old) were randomly assigned to two experimental groups: an untreated control group and a group treated topically with IMQ (IMQ-treated) for 4 or 8 weeks. A group of IMQ-treated mice that take a combination of the antioxidants tempol and apocynin, and another treated IL-17-neutralizing antibody were also performed.
RESULTS: TLR7 activation gradually increased blood pressure, associated with elevated plasma levels of anti-dsDNA autoantibodies, splenomegaly, hepatomegaly, and severe expansion of splenic immune cells with an imbalance between proinflammatory T cells and regulatory T cells. TLR7 activation induced a marked vascular remodeling in mesenteric arteries characterized by an increased media--lumen ratio (≈40%), and an impaired endothelium-dependent vasorelaxation in aortas from wild-type mice after 8 weeks of treatment. In addition, an increased ROS production, as a result of the upregulation of NADPH oxidase subunits, and an enhanced vascular inflammation were found in aortas from IMQ-treated mice. These functional and structural vascular alterations induced by IMQ were improved by antioxidant treatment. Anti-IL-17 treatment reduced blood pressure and improved endothelial dysfunction in IMQ-treated mice.
CONCLUSION: Our results demonstrate that TLR7 activation induces the development of hypertension and vascular damage in BALB/c mice, and further underscore the increased vascular inflammation and oxidative stress, mediated in part by IL-17, as key factors contributing to cardiovascular complications in this TLR7-driven lupus autoimmunity model.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32004206     DOI: 10.1097/HJH.0000000000002368

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

Review 1.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

2.  Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.

Authors:  Rahul M Kakalij; Del L Dsouza; Erika I Boesen
Journal:  Front Physiol       Date:  2022-07-06       Impact factor: 4.755

3.  Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus.

Authors:  Daniel M McClung; William J Kalusche; Katie E Jones; Michael J Ryan; Erin B Taylor
Journal:  Physiol Rep       Date:  2021-02

Review 4.  Vascular Stress Signaling in Hypertension.

Authors:  Stephanie M Cicalese; Josiane Fernandes da Silva; Fernanda Priviero; R Clinton Webb; Satoru Eguchi; Rita C Tostes
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

5.  Trimethylamine N-Oxide Promotes Autoimmunity and a Loss of Vascular Function in Toll-like Receptor 7-Driven Lupus Mice.

Authors:  Cristina González-Correa; Javier Moleón; Sofía Miñano; Néstor de la Visitación; Iñaki Robles-Vera; Manuel Gómez-Guzmán; Rosario Jiménez; Miguel Romero; Juan Duarte
Journal:  Antioxidants (Basel)       Date:  2021-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.